Alaunos Therapeutics, Inc. (TCRT) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US98973P3091

Price
1.63 USD
Market cap
3.18 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Alaunos Therapeutics, Inc. financials

Fiscal year2025
Revenue5,000.00 USD
Operating income-4.23 m USD
EBIT-4.18 m USD
Net income-4.18 m USD
Diluted EPS – continuing operations-2.20 USD

Full history since 2001, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.